دورية أكاديمية
أعرض في EDS

Enhancing the hepatitis B care cascade in Australia: A cost-effectiveness model.

التفاصيل البيبلوغرافية
العنوان: Enhancing the hepatitis B care cascade in Australia: A cost-effectiveness model.
المؤلفون: Xiao Y; Burnet Institute, Melbourne, Vic, Australia.; Department of Gastroenterology, St Vicent's Hospital, Melbourne, Vic, Australia.; University of Melbourne, Melbourne, Vic, Australia., Howell J; Burnet Institute, Melbourne, Vic, Australia.; Department of Gastroenterology, St Vicent's Hospital, Melbourne, Vic, Australia.; University of Melbourne, Melbourne, Vic, Australia.; Monash University, Melbourne, Vic, Australia., van Gemert C; Burnet Institute, Melbourne, Vic, Australia.; University of Melbourne, Melbourne, Vic, Australia., Thompson AJ; Department of Gastroenterology, St Vicent's Hospital, Melbourne, Vic, Australia.; University of Melbourne, Melbourne, Vic, Australia., Seaman CP; Burnet Institute, Melbourne, Vic, Australia.; Monash University, Melbourne, Vic, Australia., McCulloch K; University of Melbourne, Melbourne, Vic, Australia.; WHO Collaborating Centre for Viral Hepatitis, Melbourne, Vic, Australia.; Victorian Infectious Diseases Reference Laboratory, Melbourne, Vic, Australia.; The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia., Scott N; Burnet Institute, Melbourne, Vic, Australia.; Monash University, Melbourne, Vic, Australia., Hellard ME; Burnet Institute, Melbourne, Vic, Australia.; University of Melbourne, Melbourne, Vic, Australia.; Monash University, Melbourne, Vic, Australia.; The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia.; School of Population Health, Monash University, Melbourne, Vic, Australia.; Department of Infectious Diseases, Alfred Hospital, Melbourne, Vic, Australia.
المصدر: Journal of viral hepatitis [J Viral Hepat] 2020 May; Vol. 27 (5), pp. 526-536. Date of Electronic Publication: 2020 Jan 03.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 9435672 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2893 (Electronic) Linking ISSN: 13520504 NLM ISO Abbreviation: J Viral Hepat Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Oxford ; Boston : Blackwell Scientific Publications, 1994-
مواضيع طبية MeSH: Cost-Benefit Analysis* , Hepatitis B*/economics , Hepatitis B*/therapy, Australia ; Humans ; Markov Chains ; Quality-Adjusted Life Years
مستخلص: If Australia is to successfully eliminate hepatitis B as a public health threat, it will need to enhance the chronic hepatitis B (CHB) care cascade. This study used a Markov model to assess the impact, cost and cost-effectiveness of scaling up CHB diagnosis, linkage to care and treatment to reach national and international elimination targets for hepatitis B in Australia. Compared to continued current trends, the model calculated the difference in care cascade projection, disability-adjusted life years (DALYs), costs and the incremental cost-effectiveness ratio (ICER), of scaling up CHB diagnosis, linkage to care and treatment to reach: (a) Australia's 2022 national targets and (b) the WHO's 2030 global targets. Achieving the national and WHO targets had ICERs of A$13 435 (A$10 236-A$21 165) and A$14 482 (A$13 031-A$25 641) per DALY averted between 2016 and 2030 in Australia, respectively. However, this excluded implementation and demand generation costs. The ICER for the National Strategy and WHO Strategy remained under A$50 000 per DALY averted if Australia spent up to A$328 or A$538 million, respectively, per annum (for 2016-2030) on implementation and demand generation activities. Sensitivity analysis showed that cost-effectiveness was predominately driven by the cost of CHB treatment and influenced by disease progression rates. Hence for Australia to reach the National Hepatitis B Strategy 2022 targets and WHO Strategy 2030 targets, it requires an improvement in the CHB care cascade. We estimated it is cost-effective to spend up to A$328 million or A$538 million per year to reach the National and WHO Strategy targets, respectively.
(© 2019 John Wiley & Sons Ltd.)
References: Razavi-Shearer D, Gamkrelidze I, Nguyen MH, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383-403.
WHO. Global hepatitis report, 2017 [Internet]. Geneva: World Health Organization; 2017.
Liaw YF.Natural History of Chronic Hepatitis B Virus Infection. In: Thomas HC, Lok ASF, Locarnini SA, Zuckerman AJ, (Eds). Viral Hepatitis. 4th ed, 2013:143-153.
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-1273 e1.
Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy. J Hepatol. 2015;62(4):956-967.
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:29.
Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261-283.
Digestive Health Foundation, Gastroenterological Society of Australia. Australian and New Zealand Chronic Hepatitis B (CHB) Recommendations 2ND Edition 2009/10. Secondary Australian and New Zealand Chronic Hepatitis B (CHB) Recommendations 2ND Edition 2009/10 2010. https://www.gesa.org.au/resources/clinical-guidelines-and-updates/chronic-hepatitis-b/.
MacLachlan J, Thomas L, Cowie B, Allard N.Hepatitis B Mapping Project: Estimates of geographic diversity in chronic hepatitis B prevalence, diagnosis, monitoring and treatment - National Report 2017. 4 ed, 2019.
Romero N, McCulloch K, Allard N, MacLachlan J, Cowie B. National Surveillance for Hepatitis B Indicators: Measuring the progress towards the targets of the National Hepatitis B Strategy - Annual Report 2017. Melbourne: WHO Collaborating Centre for Viral Hepatitis, The Doherty Institute, 2019.
Kirby Institute. National Blood-borne Viruses and Sexually Transmissible Infections Surveillance and Monitoring Report, 2018. 2018.
WHO. Global Health Sector Strategy on Viral Hepatitis 2016-2021, 2016.
Department of Health. Third National Hepatitis B Strategy 2018-2022, 2018.
McCulloch K, Romero N, MacLachlan J, Allard N, Cowie B. Modelling progress towards elimination of hepatitis B in Australia. Hepatology 2019; https://doi.org/10.1002/hep.30899 [published Online First: Epub Date].
AIHW. Cancer data in Australia, 2018.
Hong TP, Gow PJ, Fink M, et al. Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study. Med J Aust. 2018;209(8):348-354.
MacLachlan J, Thomas L, Cowie B, Allard N.Hepatitis B Mapping Project: Estimates of geographic diversity in chronic hepatitis B prevalence, diagnosis, monitoring and treatment - National Report 2016. 4 ed, 2018.
Stephen Daniel B. Community Approach Targeting Cirrhosis and Hepatocellular carcinoma - CATCH. Monash University, 2019.
Bell SJ, Lau A, Thompson A, et al. Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients. J Clin Virol. 2005;32(2):122-127.
McCulloch K. HBV Model Data requested updated (Email communication), 2019.
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335-352.
Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int. 2016;36(9):1239-1251.
Lin X, Robinson NJ, Thursz M, et al. Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: Review of disease progression. J Gastroenterol Hepatol. 2005;20(6):833-843.
Department of Health. Pharmaceutical Benefits Scheme (PBS). Secondary Pharmaceutical Benefits Scheme (PBS) 2018. http://www.pbs.gov.au/pbs/home.
Department of Health. MBS Online. Secondary MBS Online 13 December 2018. http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Home.
Pharmaceutical Benefits Advisory Committee. Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee (version 5.0). In: Australian Government Department of Health, ed., 2016.
Nguyen NH, Nguyen V, Trinh HN, Lin B, Nguyen MH. Treatment eligibility of patients with chronic hepatitis B initially ineligible for therapy. Clin Gastroenterol Hepatol. 2013;11(5):565-571.
Uribe LA, Nguyen N, Kim L, et al. Rates of treatment eligibility in follow-up of patients with chronic hepatitis B (CHB) across various clinical settings who were initially ineligible at presentation. Digest Dis Sci. 2016;61(2):618-625.
Lieveld FI, van Vlerken LG, Siersema PD, van Erpecum KJ. Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review. Ann Hepatol. 2013;12(3):380-391.
Nayagam S, Thursz M, Sicuri E, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16(12):1399-1408.
Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Disability Weights. Secondary Global Burden of Disease Study 2017 (GBD 2017) Disability Weights 2018. http://ghdx.healthdata.org/gbd-2017.
Hill A, Gotham D, Cooke G, et al. Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. J Virus Eradic. 2015;1(2):103-110.
Australian Institute of Health and Welfare. Health expenditure Australia 2016-17. Health and welfare expenditure series no. 64. Cat. no. HWE 74. Canberra: AIHW, 2018.
Scalone L, Fagiuoli S, Ciampichini R, et al. The societal burden of chronic liver diseases: results from the COME study. BMJ Open Gastroenterol. 2015;2(1):e000025.
MacLachlan JH, Cowie BC. Cultural and linguistic diversity of people living with chronic hepatitis B in 2011-2016: changing migration, shifting epidemiology. Aust N Zeal J Public Health. 2018;42(5):441-443.
Liaw Y-F. Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients. J Hepatol. 2018;68(5):1102-1104.
Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: From discovery to regulatory approval. Hepatology. 2017;66(4):1296-1313.
Shimakawa Y, Lemoine M, Njai HF, et al. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. Gut. 2016;65(12):2007-2016.
Poh Z, Goh BB, Chang PE, Tan CK. Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance. Eur J Gastroenterol Hepatol. 2015;27(6):638-643.
Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther. 2010;15(2):133-143.
Zhou K, Contag C, Whitaker E, Terrault N. Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses. Lancet Gastroenterol Hepatol. 2019;4(3):227-238.
Chen Y-C, Chu C-M, Yeh C-T, Liaw Y-F. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int. 2007;1(1):267-273.
Nayagam S, Conteh L, Sicuri E, et al. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. Lancet Global Health. 2016;4(8):e568-e578.
Tong MJ, Hsien C, Song JJ, et al. Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis. Digest Dis Sci. 2009;54(6):1337-1346.
Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468-475.
Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis. Hepatology. 2013;58(5):1537-1547.
Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010;52(2):176-182.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460.
Wallace MC, Preen DB, Short MW, Adams LA, Jeffrey GP. Hepatocellular carcinoma in Australia 1982-2014: Increasing incidence and improving survival. Liver Int. 2019;39(3):522-530.
Wigg AJ, Chin JK, Muller KR, Ramachandran J, Woodman RJ, Kaambwa B. Cost-effectiveness of a chronic disease management model for cirrhosis: Analysis of a randomized controlled trial. J Gastroenterol Hepatol. 2018;33(9):1634-1640.
فهرسة مساهمة: Keywords: care cascade; cost-effectiveness analysis; hepatitis B
تواريخ الأحداث: Date Created: 20191220 Date Completed: 20210809 Latest Revision: 20210809
رمز التحديث: 20240628
DOI: 10.1111/jvh.13252
PMID: 31856377
قاعدة البيانات: MEDLINE
الوصف
تدمد:1365-2893
DOI:10.1111/jvh.13252